| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Pathology,
2 Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, U.S.A.
and3 Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, U.S.A.
and4 Lions Human Immunology Laboratories, Queensland University, Brisbane, Australia
Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index 
5.0) to one or more E7 peptides were observed in 28.6% (12 of 42) of patients and 23.1% (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6% (seven of 11) showed a positive LP response compared with 14.3% (two of 14) of women infected with other HPV types (P = 0.02), 17.6% (three of 17) negative for HPV (P = 0.02) and 23.1% (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4% (five of 11) of patients infected with HPV -16, -31 or -33 compared with 7.1% (one of 14) patients infected with other HPVs (P = 0.04), 5.9% (one of 17) of women negative for HPV (P = 0.02) and 7.7% (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17–37, 37–54 and 62–80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72–97) was present in 7.7% (one of 13) of controls, 35.3% (six of 17) of HPV-negative patients, 42.9% (six of 14) of patients infected with other HPVs, and only 9.1% (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72–97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.
Received 23 December 1993;
accepted 8 April 1994.
This article has been cited by other articles:
|
|
 |
|
  J. Palefsky Biology of HPV in HIV Infection Adv. Dent. Res., April 1, 2006; 19(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Luxton, R. Nath, N. Derias, A. Herbert, and P. S. Shepherd Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment J. Gen. Virol., May 1, 2003; 84(5): 1063 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kadish, P. Timmins, Y. Wang, G. Y. F. Ho, R. D. Burk, J. Ketz, W. He, S. L. Romney, A. Johnson, R. Angeletti, et al. Regression of Cervical Intraepithelial Neoplasia and Loss of Human Papillomavirus (HPV) Infection Is Associated with Cell-mediated Immune Responses to an HPV Type 16 E7 Peptide Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 483 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scott, M. Nakagawa, and A.-B. Moscicki Cell-Mediated Immune Response to Human Papillomavirus Infection Clin. Vaccine Immunol., March 1, 2001; 8(2): 209 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Shi, P. Bu, J. Liu, A. Polack, S. Fisher, and L. Qiao Human Papillomavirus Type 16 E7 DNA Vaccine: Mutation in the Open Reading Frame of E7 Enhances Specific Cytotoxic T-Lymphocyte Induction and Antitumor Activity J. Virol., September 1, 1999; 73(9): 7877 - 7881. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
